1. Catalog
  2. Prevalence of Primary Aldosteronism in Primary Car ...
Prevalence of Primary Aldosteronism in Primary Care
(5)
Image For Activity Cover
Availability
Retired
Cost
$0.00
Credit Offered
No Credit Offered
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended
This on-demand course is the recorded live webinar hosted on 04/15/2022.

Primary aldosteronism is the most common endocrine cause of hypertension. Its true prevalence remains unclear and a delay in its diagnosis has identified primary aldosteronism as a public health issue. The previously established concept that this condition is a rare disorder has been disproved. More importantly, it has led to reexamining current screening and diagnosis guidelines. 

The aim of this course is to review the current primary aldosteronism screening guidelines, explore proposed approaches to optimize its diagnosis, and highlight the urgency in identifying and treating primary aldosteronism preventing associated cardiovascular and cerebrovascular events which can be potentially modifiable with targeted therapy.

The intended audience for this activity is health care providers who care for patients in a primary care setting and the presentation is based on current research, data and studies.
  1. Underline that primary aldosteronism is not a rare disorder and it is frequently underdiagnosed in the clinical practice.
  2. Describe the current notion of primary aldosteronism.
  3. Review the most recent recommended clinical approach, screening, and diagnostic guidelines and study-based suggested modifications to these recommendations which may optimize recognition of primary aldosteronism.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

FACULTY AND DISCLOSURES
  • Camila Villavicencio, MD, 3rd-year Medicine resident at Metropolitan Hospital in NYC affiliated with New York Medical College.

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported no relevant financial relationships.

The Endocrine Society staff report no relevant financial relationships.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274       
   
Android App Download IOS App Download Powered By